950831-50-2

Basic information

• Product Name: C₃₉H₃₈N₃O₉P
• CAS NO: 950831-50-2
• Molecular Weight: 723.719
• Mol File: 950831-50-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₃₉H₃₈N₃O₉P(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₉H₃₈N₃O₉P(950831-50-2)
• EPA Substance Registry System: C₃₉H₃₈N₃O₉P(950831-50-2)

Safety Data

• Hazardous Substances Data: 950831-50-2(Hazardous Substances Data)

Upstream product

• 35661-40-6 N-Fmoc L-Phe 
• 147762-53-6 N-(fluorenylmethyloxycarbonyl)tyrosine-O-phosphate 
• 581-96-4 2-naphthylacetic acid 

Downstream Products

• 950831-51-3 Nap-Phe-Phe-Tyr-OH 

Relevant articles and documents

Alkaline phosphatase-triggered assembly of etoposide enhances its anticancer effect

Etoposide is a cancer-targeting drug but an overdose of etoposide leads to immunosuppression in patients. Therefore, the development of a new strategy to enhance its anticancer effect, while in the meantime alleviating its adverse effects, is important but challenging. In this work, with the assistance of a hydrogelator precursor Nap-Phe-Phe-Tyr(H2PO3)-OH (1P), etoposide phosphate (EP) was subjected to alkaline phosphatase (ALP)-triggered assembly, which obviously enhanced its anticancer efficacy in vitro and in vivo. In vitro tests indicated that the assembly of EP with 1P resulted in a slow release of etoposide and long-term inhibitory effects on HeLa cells. In vivo experiments indicated that, compared with those of EP-treated mice, the tumor growth of EP + 1P-treated mice was further inhibited while their body weight loss was alleviated. We envision that our hydrogelator-assisted assembly strategy could be applied to enhance the therapeutic effects of more drugs, while in the meantime alleviating their adverse effects in the future.